Osteoporosis and associated events are important and costly side-effects of LHRHa.7, 9 Strategies to mitigate LHRHa-induced bone loss include use of bisphosphonates, targeting of RANKL (with, for example, denosumab), and use of selective oestrogen-receptor modulators. The gene discussed is TNFSF11; the disease is osteoporosis.